

# Ie-Ming Shih

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2914247/ie-ming-shih-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

274  
papers

27,330  
citations

87  
h-index

160  
g-index

284  
ext. papers

31,323  
ext. citations

8.1  
avg, IF

7.23  
L-index

#	Paper	IF	Citations
274	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2021</b> , 163, 246-253	4.9	8
273	Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report.. <i>Gynecologic Oncology Reports</i> , <b>2021</b> , 38, 100877	1.3	0
272	Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy. <i>IScience</i> , <b>2021</b> , 24, 103297	6.1	1
271	Sub-millimeter endoscope demonstrates feasibility of in vivo reflectance imaging, fluorescence imaging, and cell collection in the fallopian tubes. <i>Journal of Biomedical Optics</i> , <b>2021</b> , 26,	3.5	1
270	The Origin of Ovarian Cancer Species and Precancerous Landscape. <i>American Journal of Pathology</i> , <b>2021</b> , 191, 26-39	5.8	24
269	Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma. <i>Journal of Pathology</i> , <b>2021</b> , 253, 119-128	9.4	10
268	Uterine serous carcinoma: key advances and novel treatment approaches. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 1165-1174	3.5	6
267	A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening. <i>Laboratory Investigation</i> , <b>2021</b> , 101, 1505-1512	5.9	0
266	Mutation and methylation profiles of ectopic and eutopic endometrial tissues. <i>Journal of Pathology</i> , <b>2021</b> , 255, 387-398	9.4	0
265	Epigenomic Reprogramming toward Mesenchymal-Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis. <i>Cell Reports</i> , <b>2020</b> , 33, 108473	10.6	8
264	Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. <i>Nature Communications</i> , <b>2020</b> , 11, 2717	17.4	12
263	Assessing aneuploidy with repetitive element sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 4858-4863	11.5	26
262	Epithelial Cells in Endometriosis and Adenomyosis Upregulate STING Expression. <i>Reproductive Sciences</i> , <b>2020</b> , 27, 1276-1284	3	7
261	Low-grade serous ovarian cancer: State of the science. <i>Gynecologic Oncology</i> , <b>2020</b> , 156, 715-725	4.9	28
260	NAC1 attenuates BCL6 negative autoregulation and functions as a BCL6 coactivator of FOXQ1 transcription in cancer cells. <i>Aging</i> , <b>2020</b> , 12, 9275-9291	5.6	3
259	The Origin and Pathogenesis of Endometriosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2020</b> , 15, 71-95	34	78
258	Oncogenic BRAF and KRAS mutations in endosalpingiosis. <i>Journal of Pathology</i> , <b>2020</b> , 250, 148-158	9.4	7

257	Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. <i>International Journal of Gynecological Pathology</i> , <b>2020</b> , 39, 26-35	3.2	24
256	Pathology and Pathogenesis of Adenomyosis. <i>Seminars in Reproductive Medicine</i> , <b>2020</b> , 38, 108-118	1.4	6
255	Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers. <i>Cancer Research</i> , <b>2020</b> , 80, 4514-4526	10.1	19
254	Urothelial Carcinomas With Trophoblastic Differentiation, Including Choriocarcinoma: Clinicopathologic Series of 16 Cases. <i>American Journal of Surgical Pathology</i> , <b>2020</b> , 44, 1322-1330	6.7	6
253	Methylomic Landscapes of Ovarian Cancer Precursor Lesions. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6310-6320	2.9	4
252	Gestational Trophoblastic Lesions <b>2020</b> , 871-903		
251	Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer. <i>EBioMedicine</i> , <b>2019</b> , 47, 184-194	8.8	6
250	PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8 T-cell Function. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 257-268	12.5	51
249	Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5584-5594	12.9	44
248	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , <b>2019</b> , 125, 1963-1972	6.4	22
247	Cytomorphologic and molecular analyses of fallopian tube fimbrial brushings for diagnosis of serous tubal intraepithelial carcinoma. <i>Cancer Cytopathology</i> , <b>2019</b> , 127, 192-201	3.9	
246	TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2 $\alpha$ as a therapeutic target. <i>Journal of Pathology</i> , <b>2019</b> , 248, 363-376	9.4	10
245	Follicular fluid has more to offer: Insulin-like growth factor axis on ovarian carcinogenesis. <i>EBioMedicine</i> , <b>2019</b> , 41, 30-31	8.8	0
244	Epithelial Tumors of the Ovary <b>2019</b> , 841-966		6
243	Gestational Trophoblastic Tumors and Related Tumorlike Lesions <b>2019</b> , 1307-1375		
242	-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma. <i>Oncotarget</i> , <b>2019</b> , 10, 6870-6878	3.3	4
241	Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment. <i>Nature Communications</i> , <b>2019</b> , 10, 733	17.4	19
240	Analysis of Telomere Lengths in p53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer. <i>American Journal of Surgical Pathology</i> , <b>2019</b> , 43, 1083-1091	6.7	5

239	Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2019</b> , 43, 1462-1472	6.7	15
238	Long Interspersed Nuclear Element 1 Retrotransposons Become Deregulated during the Development of Ovarian Cancer Precursor Lesions. <i>American Journal of Pathology</i> , <b>2019</b> , 189, 513-520	5.8	19
237	Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. <i>Journal of Pathology</i> , <b>2019</b> , 248, 41-50	9.4	44
236	T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. <i>Modern Pathology</i> , <b>2019</b> , 32, 576-584	9.8	16
235	Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors. <i>Molecular and Cellular Proteomics</i> , <b>2019</b> , 18, 448-460	7.6	11
234	Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway. <i>Oncogene</i> , <b>2018</b> , 37, 3778-3789	9.2	15
233	Precancerous Lesions of Ovarian Cancer-A US Perspective. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 692-693	9.7	8
232	Independent development of endometrial epithelium and stroma within the same endometriosis. <i>Journal of Pathology</i> , <b>2018</b> , 245, 265-269	9.4	34
231	Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. <i>Cell Reports</i> , <b>2018</b> , 22, 3393-3400	10.6	50
230	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	110
229	Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma. <i>Gynecologic Oncology</i> , <b>2018</b> , 150, 426-431	4.9	17
228	Methylomic Analysis of Ovarian Cancers Identifies Tumor-Specific Alterations Readily Detectable in Early Precursor Lesions. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 6536-6547	12.9	28
227	Epithelial Tumors of the Ovary <b>2018</b> , 1-128		
226	Epithelial Tumors of the Ovary <b>2018</b> , 1-128		
225	Gestational Trophoblastic Tumors and Related Tumorlike Lesions <b>2018</b> , 1-71		
224	Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. <i>Cancer Prevention Research</i> , <b>2018</b> , 11, 697-706	3.2	33
223	Reply to Haffner et al.: DNA hypomethylation renders tumors more immunogenic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E8583-E8584	11.5	2
222	Human transposon insertion profiling: Analysis, visualization and identification of somatic LINE-1 insertions in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E733-E740	11.5	57

221	Tubal origin of ovarian cancer—the double-edged sword of haemoglobin. <i>Journal of Pathology</i> , <b>2017</b> , 242, 3-6	9.4	15
220	Cancer-Associated Mutations in Endometriosis without Cancer. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1835-1848	59.2	310
219	Cancer Implications for Patients with Endometriosis. <i>Seminars in Reproductive Medicine</i> , <b>2017</b> , 35, 110-116	4	45
218	Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. <i>Nature Communications</i> , <b>2017</b> , 8, 990	17.4	109
217	High grade serous ovarian carcinomas originate in the fallopian tube. <i>Nature Communications</i> , <b>2017</b> , 8, 1093	17.4	325
216	CINdex: A Bioconductor Package For Analysis of Chromosome Instability in DNA Copy Number Data. <i>Cancer Informatics</i> , <b>2017</b> , 16, 1176935117746637	2.4	6
215	Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma. <i>Human Pathology</i> , <b>2017</b> , 68, 87-91	3.7	12
214	PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases. <i>International Journal of Gynecological Pathology</i> , <b>2017</b> , 36, 146-153	3.2	92
213	Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?. <i>Gynecologic Oncology</i> , <b>2017</b> , 147, 85-91	4.9	49
212	Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E10981-E10990	11.5	132
211	CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis. <i>Modern Pathology</i> , <b>2017</b> , 30, 297-303	9.8	38
210	The novel ZIP4 regulation and its role in ovarian cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 90090-90107	3.3	22
209	Elucidating the pathogenesis of synchronous and metachronous tumors in a woman with endometrioid carcinomas using a whole-exome sequencing approach. <i>Journal of Physical Education and Sports Management</i> , <b>2017</b> , 3,	2.8	10
208	CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , <b>2016</b> , 29, 1254-61	9.8	54
207	Biologically inspired survival analysis based on integrating gene expression as mediator with genomic variants. <i>Computers in Biology and Medicine</i> , <b>2016</b> , 77, 231-9	7	1
206	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. <i>Cancer Prevention Research</i> , <b>2016</b> , 9, 713-20	3.2	6
205	Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. <i>International Journal of Gynecological Pathology</i> , <b>2016</b> , 35, 48-55	3.2	110
204	Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. <i>Cell</i> , <b>2016</b> , 166, 755-765	56.2	544

203	Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells. <i>Journal of Biological Chemistry</i> , <b>2016</b> , 291, 9690-9	5.4	32
202	The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. <i>American Journal of Pathology</i> , <b>2016</b> , 186, 733-47	5.8	506
201	CHIP-BIT: Bayesian inference of target genes using a novel joint probabilistic model of CHIP-seq profiles. <i>Nucleic Acids Research</i> , <b>2016</b> , 44, e65	20.1	6
200	Diagnostic potential of tumor DNA from ovarian cyst fluid. <i>ELife</i> , <b>2016</b> , 5,	8.9	25
199	Expression of Cell Competition Markers at the Interface between p53 Signature and Normal Epithelium in the Human Fallopian Tube. <i>PLoS ONE</i> , <b>2016</b> , 11, e0156069	3.7	0
198	Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1. <i>Cancer Research</i> , <b>2016</b> , 76, 6351-6361	10.1	45
197	Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. <i>Cancer Cell</i> , <b>2015</b> , 28, 82-96	24.3	96
196	Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4652-62	12.9	37
195	ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. <i>Cancer Discovery</i> , <b>2015</b> , 5, 752-67	24.4	260
194	Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases. <i>Human Pathology</i> , <b>2015</b> , 46, 761-6	3.7	9
193	GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility. <i>American Journal of Surgical Pathology</i> , <b>2015</b> , 39, 101-8	6.7	56
192	Laminin C1 expression by uterine carcinoma cells is associated with tumor progression. <i>Gynecologic Oncology</i> , <b>2015</b> , 139, 338-44	4.9	30
191	Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , <b>2015</b> , 28, 437-45	9.8	14
190	UNDO: a Bioconductor R package for unsupervised deconvolution of mixed gene expressions in tumor samples. <i>Bioinformatics</i> , <b>2015</b> , 31, 137-9	7.2	42
189	KDDN: an open-source Cytoscape app for constructing differential dependency networks with significant rewiring. <i>Bioinformatics</i> , <b>2015</b> , 31, 287-9	7.2	16
188	BACOM2.0 facilitates absolute normalization and quantification of somatic copy number alterations in heterogeneous tumor. <i>Scientific Reports</i> , <b>2015</b> , 5, 13955	4.9	5
187	Clonality analysis of combined Brenner and mucinous tumours of the ovary reveals their monoclonal origin. <i>Journal of Pathology</i> , <b>2015</b> , 237, 146-51	9.4	36
186	Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. <i>Gynecologic Oncology Research and Practice</i> , <b>2015</b> , 2, 1	4.5	19

185	Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors. <i>Journal of Pathology: Clinical Research</i> , <b>2015</b> , 1, 186-93	5.3	23
184	Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. <i>Nature Medicine</i> , <b>2015</b> , 21, 231-8	50.5	397
183	Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma--an update. <i>Journal of Obstetrics and Gynaecology Research</i> , <b>2015</b> , 41, 6-11	1.9	26
182	Expression Patterns of VEGF and Flk-1 in Human Endometrium during the Menstrual Cycle. <i>Journal of Reproduction and Infertility</i> , <b>2015</b> , 16, 3-9	1.5	4
181	Molecular analysis of ovarian mucinous carcinoma reveals different cell of origins. <i>Oncotarget</i> , <b>2015</b> , 6, 22949-58	3.3	14
180	Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. <i>Journal of Pathology</i> , <b>2014</b> , 232, 473-81	9.4	68
179	Long interspersed element-1 protein expression is a hallmark of many human cancers. <i>American Journal of Pathology</i> , <b>2014</b> , 184, 1280-6	5.8	158
178	A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. <i>Journal of Pathology</i> , <b>2014</b> , 233, 228-37	9.4	93
177	The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis. <i>Modern Pathology</i> , <b>2014</b> , 27, 231-7	9.8	24
176	Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2014</b> , 9, 27-45	34	113
175	ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. <i>Human Pathology</i> , <b>2014</b> , 45, 2233-9	3.7	23
174	RSF1 is a positive regulator of NF- $\kappa$ B-induced gene expression required for ovarian cancer chemoresistance. <i>Cancer Research</i> , <b>2014</b> , 74, 2258-69	10.1	27
173	Identification of the NAC1-regulated genes in ovarian cancer. <i>American Journal of Pathology</i> , <b>2014</b> , 184, 133-40	5.8	15
172	Gene expression signatures of primary and metastatic uterine leiomyosarcoma. <i>Human Pathology</i> , <b>2014</b> , 45, 691-700	3.7	55
171	The emerging roles of ARID1A in tumor suppression. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 655-64	4.6	148
170	ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. <i>Modern Pathology</i> , <b>2014</b> , 27, 255-61	9.8	86
169	Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. <i>Modern Pathology</i> , <b>2014</b> , 27, 1014-9	9.8	46
168	Notch3 interactome analysis identified WWP2 as a negative regulator of Notch3 signaling in ovarian cancer. <i>PLoS Genetics</i> , <b>2014</b> , 10, e1004751	6	46

167	Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants. <i>Journal of Pathology</i> , <b>2014</b> , 232, 16-22	9.4	42
166	BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors. <i>American Journal of Surgical Pathology</i> , <b>2014</b> , 38, 1603-11	6.7	42
165	Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	83
164	Characterization of the immune cell repertoire in the normal fallopian tube. <i>International Journal of Gynecological Pathology</i> , <b>2014</b> , 33, 581-91	3.2	27
163	Screening for Ovarian Cancer: A Reality Check. <i>Current Obstetrics and Gynecology Reports</i> , <b>2013</b> , 2, 73-75	0.6	1
162	TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 6021-6	11.5	968
161	Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 167ra4	17.5	208
160	Dedifferentiated endometrioid adenocarcinoma: An under-recognized but aggressive tumor?. <i>Gynecologic Oncology Case Reports</i> , <b>2013</b> , 5, 25-7		11
159	Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 3839-49	7.5	52
158	Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. <i>Histopathology</i> , <b>2013</b> , 62, 44-58	7.3	190
157	High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome. <i>Gynecologic Oncology</i> , <b>2013</b> , 128, 500-5	4.9	16
156	Discriminant and Network Analysis to Study Origin of Cancer <b>2013</b> , 193-214		
155	Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 1342-8	6.7	62
154	Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. <i>Advances in Anatomic Pathology</i> , <b>2013</b> , 20, 45-52	5.1	82
153	Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. <i>Journal of Pathology</i> , <b>2013</b> , 229, 559-68	9.4	29
152	Genomic and network analysis to study the origin of ovarian cancer. <i>Systems Biomedicine (Austin, Tex)</i> , <b>2013</b> , 1, 55-64		1
151	The roles of ARID1A in gynecologic cancer. <i>Journal of Gynecologic Oncology</i> , <b>2013</b> , 24, 376-81	4	46
150	Loss of NAC1 expression is associated with defective bony patterning in the murine vertebral axis. <i>PLoS ONE</i> , <b>2013</b> , 8, e69099	3.7	13



149	Molecular Pathology of Ovarian Cancer <b>2013</b> , 129-149		1
148	Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 1503-13	9.7	191
147	Dysfunction of nucleus accumbens-1 activates cellular senescence and inhibits tumor cell proliferation and oncogenesis. <i>Cancer Research</i> , <b>2012</b> , 72, 4262-75	10.1	19
146	Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells. <i>American Journal of Pathology</i> , <b>2012</b> , 180, 1179-1188	5.8	25
145	Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. <i>Human Pathology</i> , <b>2012</b> , 43, 2197-206	3.7	52
144	Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. <i>Neoplasia</i> , <b>2012</b> , 14, 986-93	6.4	71
143	Pathogenesis and new therapeutic targets of ovarian cancer. <i>Journal of Oncology</i> , <b>2012</b> , 2012, 867512	4.5	1
142	DNA Damage Response is Prominent in Ovarian High-Grade Serous Carcinomas, Especially Those with Rsf-1 (HBXAP) Overexpression. <i>Journal of Oncology</i> , <b>2012</b> , 2012, 621685	4.5	12
141	TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. <i>Journal of Pathology</i> , <b>2012</b> , 226, 421-6	9.4	252
140	Low-grade serous carcinomas of the ovary contain very few point mutations. <i>Journal of Pathology</i> , <b>2012</b> , 226, 413-20	9.4	154
139	A fluorescence light-up Ag nanocluster probe that discriminates single-nucleotide variants by emission color. <i>Journal of the American Chemical Society</i> , <b>2012</b> , 134, 11550-8	16.4	213
138	Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma. <i>Cancer</i> , <b>2012</b> , 118, 2846-57	6.4	39
137	Ovarian Cancer Is an Imported Disease: Fact or Fiction?. <i>Current Obstetrics and Gynecology Reports</i> , <b>2012</b> , 1, 1-9	0.6	91
136	The role of forkhead box Q1 transcription factor in ovarian epithelial carcinomas. <i>International Journal of Molecular Sciences</i> , <b>2012</b> , 13, 13881-93	6.3	21
135	Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. <i>International Journal of Gynecological Pathology</i> , <b>2012</b> , 31, 297-303	3.2	60
134	Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma. <i>International Journal of Gynecological Pathology</i> , <b>2012</b> , 31, 416-22	3.2	38
133	Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. <i>International Journal of Gynecological Pathology</i> , <b>2012</b> , 31, 243-53	3.2	95
132	Detecting aberrant signal transduction pathways from high-throughput data using GIST algorithm <b>2012</b> ,		1

131	Defining NOTCH3 target genes in ovarian cancer. <i>Cancer Research</i> , <b>2012</b> , 72, 2294-303	10.1	49
130	NAC1 is an actin-binding protein that is essential for effective cytokinesis in cancer cells. <i>Cancer Research</i> , <b>2012</b> , 72, 4085-96	10.1	24
129	Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. <i>International Journal of Gynecological Cancer</i> , <b>2012</b> , 22, 1310-5	3.5	113
128	The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2012</b> , 36, 1826-34	6.7	39
127	Identification of PBX1 target genes in cancer cells by global mapping of PBX1 binding sites. <i>PLoS ONE</i> , <b>2012</b> , 7, e36054	3.7	26
126	Cell cycle-dependent alteration in NAC1 nuclear body dynamics and morphology. <i>Physical Biology</i> , <b>2011</b> , 8, 015005	3	18
125	Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. <i>American Journal of Pathology</i> , <b>2011</b> , 178, 1442-7	5.8	72
124	Overexpression of a chromatin remodeling factor, RSF-1/HBXAP, correlates with aggressive oral squamous cell carcinoma. <i>American Journal of Pathology</i> , <b>2011</b> , 178, 2407-15	5.8	39
123	Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. <i>American Journal of Pathology</i> , <b>2011</b> , 179, 1608-15	5.8	328
122	Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. <i>Human Pathology</i> , <b>2011</b> , 42, 991-7	3.7	10
121	Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. <i>Human Pathology</i> , <b>2011</b> , 42, 918-31	3.7	767
120	ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. <i>Cancer Research</i> , <b>2011</b> , 71, 6718-27	10.1	306
119	Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 625-32	6.7	206
118	Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma. <i>International Journal of Gynecological Pathology</i> , <b>2011</b> , 30, 30-5	3.2	17
117	Evolution of a trophoblastic tumor from an endometrioid carcinoma--a morphological and molecular analysis. <i>International Journal of Gynecological Pathology</i> , <b>2011</b> , 30, 117-20	3.2	15
116	Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 1605-14	6.7	116
115	Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 1766-75	6.7	116
114	Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma. <i>Journal of Pathology</i> , <b>2011</b> , 224, 1-4	9.4	10

113	Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , <b>2011</b> , 24, 638-45	9.8	44
112	Trophoblastic vasculogenic mimicry in gestational choriocarcinoma. <i>Modern Pathology</i> , <b>2011</b> , 24, 646-52	9.8	19
111	Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma. <i>Modern Pathology</i> , <b>2011</b> , 24, 1139-45	9.8	25
110	Gestational Trophoblastic Tumors and Related Tumor-Like Lesions <b>2011</b> , 1075-1135		10
109	Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. <i>Journal of Oncology</i> , <b>2010</b> , 2010, 126295	4.5	54
108	Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas. <i>Journal of Oncology</i> , <b>2010</b> , 2010, 285191	4.5	44
107	Lack of a y-chromosomal complement in the majority of gestational trophoblastic neoplasms. <i>Journal of Oncology</i> , <b>2010</b> , 2010, 364508	4.5	13
106	DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1997-2008	12.9	76
105	Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 38260-9	5.4	47
104	The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 433-43	6.7	1235
103	Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. <i>International Journal of Molecular Sciences</i> , <b>2010</b> , 11, 5120-8	6.3	89
102	Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. <i>Modern Pathology</i> , <b>2010</b> , 23, 844-55	9.8	72
101	Dendritic cells transduced with Rsf-1/HBXAP gene generate specific cytotoxic T lymphocytes against ovarian cancer in vitro. <i>Biochemical and Biophysical Research Communications</i> , <b>2010</b> , 394, 633-8	3.4	3
100	Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. <i>Science</i> , <b>2010</b> , 330, 228-31	33.3	915
99	ARID1A mutations in endometriosis-associated ovarian carcinomas. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1532-43	59.2	1208
98	Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. <i>American Journal of Pathology</i> , <b>2010</b> , 177, 1087-94	5.8	137
97	HLA-G and immune evasion in cancer cells. <i>Journal of the Formosan Medical Association</i> , <b>2010</b> , 109, 248-53	7.2	50
96	Are all pelvic (nonuterine) serous carcinomas of tubal origin?. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 1407-16	6.7	333

95	Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 829-36	6.7	102
94	Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. <i>American Journal of Obstetrics and Gynecology</i> , <b>2010</b> , 203, 584.e1-22	6.4	37
93	Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. <i>PLoS ONE</i> , <b>2010</b> , 5, e11198	3.7	62
92	Jagged1 expression regulated by Notch3 and Wnt/ $\beta$ -catenin signaling pathways in ovarian cancer. <i>Oncotarget</i> , <b>2010</b> , 1, 210-8	3.3	77
91	Gestational Trophoblastic Lesions <b>2009</b> , 645-665		4
90	Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. <i>Cancer Research</i> , <b>2009</b> , 69, 4036-42	10.1	143
89	Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. <i>Cancer Research</i> , <b>2009</b> , 69, 1407-15	10.1	64
88	Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. <i>Advances in Anatomic Pathology</i> , <b>2009</b> , 16, 267-82	5.1	403
87	Pathogenesis of ovarian cancer: clues from selected overexpressed genes. <i>Future Oncology</i> , <b>2009</b> , 5, 1641-57	3.6	45
86	Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. <i>Cancer Research</i> , <b>2009</b> , 69, 2568-76	10.1	132
85	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. <i>Modern Pathology</i> , <b>2009</b> , 22, 469-75	9.8	102
84	Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. <i>Human Pathology</i> , <b>2009</b> , 40, 1453-60	3.7	59
83	Ovarian cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2009</b> , 4, 287-313	34	505
82	Advances in the diagnosis of gestational trophoblastic tumors and tumor-like lesions. <i>Expert Opinion on Medical Diagnostics</i> , <b>2009</b> , 3, 371-80		2
81	Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. <i>American Journal of Pathology</i> , <b>2009</b> , 174, 1597-601	5.8	339
80	Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. <i>American Journal of Surgical Pathology</i> , <b>2009</b> , 33, 1220-4	6.7	68
79	Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. <i>American Journal of Surgical Pathology</i> , <b>2009</b> , 33, 844-53	6.7	106
78	Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. <i>American Journal of Surgical Pathology</i> , <b>2009</b> , 33, 1504-14	6.7	142

77	Metastatic epithelioid trophoblastic tumor in a male patient with mixed germ-cell tumor of the testis. <i>American Journal of Surgical Pathology</i> , <b>2009</b> , 33, 1902-5	6.7	16
76	Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions. <i>Human Pathology</i> , <b>2008</b> , 39, 616-22	3.7	8
75	Power of the eternal youth: Nanog expression in the gestational choriocarcinoma. <i>American Journal of Pathology</i> , <b>2008</b> , 173, 911-4	5.8	11
74	Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 8852-60	10.1	53
73	The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. <i>Cancer Research</i> , <b>2008</b> , 68, 4050-7	10.1	47
72	Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. <i>Cancer Research</i> , <b>2008</b> , 68, 5716-23	10.1	101
71	Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. <i>International Journal of Gynecological Pathology</i> , <b>2008</b> , 27, 151-60	3.2	329
70	HSD3B1 as a novel trophoblast-associated marker that assists in the differential diagnosis of trophoblastic tumors and tumorlike lesions. <i>American Journal of Surgical Pathology</i> , <b>2008</b> , 32, 236-42	6.7	45
69	MicroRNA expression and identification of putative miRNA targets in ovarian cancer. <i>PLoS ONE</i> , <b>2008</b> , 3, e2436	3.7	273
68	Amplification of 11q13 in ovarian carcinoma. <i>Genes Chromosomes and Cancer</i> , <b>2008</b> , 47, 481-9	5	101
67	National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. <i>Clinical Chemistry</i> , <b>2008</b> , 54, e11-79	5.5	451
66	Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. <i>American Journal of Obstetrics and Gynecology</i> , <b>2008</b> , 198, 351-6	6.4	157
65	Biomarker Identification by Knowledge-Driven Multi-Level ICA and Motif Analysis <b>2007</b> ,		1
64	Amplicon profiles in ovarian serous carcinomas. <i>International Journal of Cancer</i> , <b>2007</b> , 120, 2613-7	7.5	104
63	Ovarian cancer specific kallikrein profile in effusions. <i>Gynecologic Oncology</i> , <b>2007</b> , 105, 501-7	4.9	39
62	Clinical and biological significance of HLA-G expression in ovarian cancer. <i>Seminars in Cancer Biology</i> , <b>2007</b> , 17, 436-43	12.7	38
61	MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. <i>Diagnostic Cytopathology</i> , <b>2007</b> , 35, 756-60	1.4	39
60	NAC-1 controls cell growth and survival by repressing transcription of Gadd45GIP1, a candidate tumor suppressor. <i>Cancer Research</i> , <b>2007</b> , 67, 8058-64	10.1	53

59	Notch signaling, gamma-secretase inhibitors, and cancer therapy. <i>Cancer Research</i> , <b>2007</b> , 67, 1879-82	10.1	354
58	Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5805-9	12.9	20
57	The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. <i>American Journal of Surgical Pathology</i> , <b>2007</b> , 31, 1007-12	6.7	126
56	Immunohistochemistry of choriocarcinoma: an aid in differential diagnosis and in elucidating pathogenesis. <i>American Journal of Surgical Pathology</i> , <b>2007</b> , 31, 1726-32	6.7	71
55	Trophogram, an immunohistochemistry-based algorithmic approach, in the differential diagnosis of trophoblastic tumors and tumorlike lesions. <i>Annals of Diagnostic Pathology</i> , <b>2007</b> , 11, 228-34	2.2	68
54	Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions. <i>Human Pathology</i> , <b>2007</b> , 38, 1030-1036	3.7	27
53	Application of human leukocyte antigen-G expression in the diagnosis of human cancer. <i>Human Immunology</i> , <b>2007</b> , 68, 272-6	2.3	24
52	Gestational trophoblastic neoplasia--pathogenesis and potential therapeutic targets. <i>Lancet Oncology, The</i> , <b>2007</b> , 8, 642-50	21.7	142
51	Pathogenesis of Gestational Trophoblastic Lesions <b>2007</b> , 157-166		3
50	Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 779-85	4.6	149
49	Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 827-31	12.9	71
48	Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. <i>Cancer Research</i> , <b>2006</b> , 66, 3754-63	10.1	104
47	Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 5944-50	12.9	89
46	A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 18739-44	11.5	104
45	Homozygous deletion of MKK4 in ovarian serous carcinoma. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 630-4	4.6	43
44	Notch3 gene amplification in ovarian cancer. <i>Cancer Research</i> , <b>2006</b> , 66, 6312-8	10.1	236
43	Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. <i>Human Pathology</i> , <b>2006</b> , 37, 1169-75	3.7	35
42	Cyclin E and p16 immunoreactivity in epithelioid trophoblastic tumor--an aid in differential diagnosis. <i>American Journal of Surgical Pathology</i> , <b>2006</b> , 30, 1105-10	6.7	69

41	Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2006</b> , 449, 31-9	5.1	73
40	Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome. <i>Human Pathology</i> , <b>2005</b> , 36, 1049-54	3.7	26
39	Activation of mitogen-activated protein kinase is required for migration and invasion of placental site trophoblastic tumor. <i>American Journal of Pathology</i> , <b>2005</b> , 167, 879-85	5.8	20
38	Apply innovative technologies to explore cancer genome. <i>Current Opinion in Oncology</i> , <b>2005</b> , 17, 33-8	4.2	31
37	Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. <i>American Journal of Surgical Pathology</i> , <b>2005</b> , 29, 218-24	6.7	336
36	HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract. <i>International Journal of Gastrointestinal Cancer</i> , <b>2005</b> , 35, 15-23		40
35	Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinoma. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , <b>2005</b> , 1730, 96-102		9
34	HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2005</b> , 96, 42-7	4.9	83
33	Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. <i>Cancer Research</i> , <b>2005</b> , 65, 1994-2000	10.1	108
32	Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 14004-9	11.5	119
31	Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 7273-9	12.9	113
30	Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. <i>Cancer Research</i> , <b>2005</b> , 65, 331-7	10.1	94
29	Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. <i>Cancer Research</i> , <b>2004</b> , 64, 6915-8	10.1	160
28	Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 6432-6	12.9	103
27	Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 3089-94	11.5	163
26	Molecular genetic analysis of ovarian serous cystadenomas. <i>Laboratory Investigation</i> , <b>2004</b> , 84, 778-84	5.9	40
25	Profiling the activity of G proteins in patient-derived tissues by rapid affinity-capture of signal transduction proteins (GRASP). <i>Proteomics</i> , <b>2004</b> , 4, 812-8	4.8	14
24	Principle and applications of digital PCR. <i>Expert Review of Molecular Diagnostics</i> , <b>2004</b> , 4, 41-7	3.8	149

23	Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. <i>American Journal of Pathology</i> , <b>2004</b> , 164, 1511-8	5.8	951
22	p63 expression is useful in the distinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations. <i>American Journal of Surgical Pathology</i> , <b>2004</b> , 28, 1177-83	6.7	128
21	Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 484-6	9.7	668
20	Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). <i>International Journal of Gynecological Pathology</i> , <b>2003</b> , 22, 37-41	3.2	101
19	Increased plasma DNA integrity in cancer patients. <i>Cancer Research</i> , <b>2003</b> , 63, 3966-8	10.1	216
18	Identifying tumor origin using a gene expression-based classification map. <i>Cancer Research</i> , <b>2003</b> , 63, 4144-9	10.1	72
17	HLA-G is a potential tumor marker in malignant ascites. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 4460-4	12.9	130
16	APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. <i>Genes Chromosomes and Cancer</i> , <b>2002</b> , 34, 9-16	5	133
15	The role of chromosomal instability in tumor initiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 16226-31	11.5	399
14	Molecular basis of gestational trophoblastic diseases. <i>Current Molecular Medicine</i> , <b>2002</b> , 2, 1-12	2.5	61
13	Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 1697-703	9.7	102
12	HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. <i>American Journal of Surgical Pathology</i> , <b>2002</b> , 26, 914-20	6.7	109
11	Diverse tumorigenic pathways in ovarian serous carcinoma. <i>American Journal of Pathology</i> , <b>2002</b> , 160, 1223-8	5.8	280
10	Molecular genetic analysis of placental site trophoblastic tumors and epithelioid trophoblastic tumors confirms their trophoblastic origin. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 1033-7	5.8	53
9	Proteomic approaches to tumor marker discovery. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2002</b> , 126, 1518-26	5	181
8	The Role of E-cadherin in the Motility and Invasion of Implantation Site Intermediate Trophoblast. <i>Placenta</i> , <b>2002</b> , 23, 706-15	3.4	32
7	Molecular genetic analysis of appendiceal mucinous adenomas in identical twins, including one with pseudomyxoma peritonei. <i>American Journal of Surgical Pathology</i> , <b>2001</b> , 25, 1095-9	6.7	29
6	The pathology of intermediate trophoblastic tumors and tumor-like lesions. <i>International Journal of Gynecological Pathology</i> , <b>2001</b> , 20, 31-47	3.2	224



5	Placental site trophoblastic tumor--past as prologue. <i>Gynecologic Oncology</i> , <b>2001</b> , 82, 413-4	4.9	12
4	Assessing tumors in living animals through measurement of urinary beta-human chorionic gonadotropin. <i>Nature Medicine</i> , <b>2000</b> , 6, 711-4	50.5	31
3	Placental site nodule and characterization of distinctive types of intermediate trophoblast. <i>Human Pathology</i> , <b>1999</b> , 30, 687-94	3.7	93
2	Ki-67 labeling index in the differential diagnosis of exaggerated placental site, placental site trophoblastic tumor, and choriocarcinoma: a double immunohistochemical staining technique using Ki-67 and Mel-CAM antibodies. <i>Human Pathology</i> , <b>1998</b> , 29, 27-33	3.7	112
1	Epithelioid trophoblastic tumor: a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma. <i>American Journal of Surgical Pathology</i> , <b>1998</b> , 22, 1393-403	6.7	268